Nav: Home

Patients frequently refuse insulin therapy, delaying blood sugar control

February 20, 2020

Boston, MA -- Patients with type 2 diabetes who have high levels of blood sugar are at greater risk of serious complications such as chronic kidney disease, heart disease and blindness. While lifestyle changes and medications can help some patients better control their blood sugar levels, type 2 diabetes tends to progress, and patients typically need more intense treatment to continue to maintain blood sugar control. Insulin offers the most robust way to control blood glucose, but insulin therapy is often delayed, sometimes by several years. A new study by investigators from Brigham and Women's Hospital finds that more than 40 percent of patients refuse a physician's recommendation of insulin therapy. The study also finds that patients who decline insulin therapy had worse blood sugar control and it took them significantly longer to lower their blood sugar levels than patients who began insulin therapy. The team's findings are published in Diabetic Medicine.

"Type 2 diabetes is a serious disease. High blood sugar levels can have a severe impact on a person's quality of life and life expectancy," said corresponding author Alexander Turchin, MD, MS, director of quality in diabetes at the Brigham. "Saying no may bear a strong influence on blood sugar levels and, down the road, complications. A few years of uncontrolled blood sugar can have a big impact."

Previously conducted clinical trials have found that just a few years of elevated blood sugar levels can lead to an increased risk of heart attack and kidney failure 10 or 20 years later. Given the consequences of uncontrolled blood sugar levels, Turchin and colleagues set out to better understand why insulin therapy initiation is frequently delayed.

The team used natural language processing -- an artificial intelligence tool that can scan through large amounts of data to pull out key phrases -- to comb through clinical narratives that physicians had recorded in patients' medical records. This allowed researchers, for the first time, to identify documented insulin decline by patients in electronic medical records notes. The study included more than 5,000 adults with type 2 diabetes who were followed by primary care physicians (PCPs) affiliated with the Brigham and Massachusetts General Hospital between 2000 and 2014.

More than 2,000 patients (43 percent) in the study declined insulin therapy. It took patients who declined insulin an average of 50 months to reach target blood sugar levels, whereas it took an average of 38 months for those who started insulin therapy when their physician recommended it. Participants were more likely to accept insulin therapy if they had diabetes complications or higher blood sugar levels or if they were already seeing an endocrinologist. Older participants and those taking other diabetes medications were less likely to accept insulin therapy.

The authors note that the study does not address the reason patients decline insulin therapy -- that generally is not noted in a patient's record. All patients in the study received care in Massachusetts where insulin costs are generally lower than in other parts of the country. Turchin would like to further investigate possible reasons in future studies as well as the long-term complications that patients who decline insulin may experience.

"Our study calls into question an assumption of therapeutic inertia -- the idea that if a patient with diabetes has high blood sugar, it's always the fault of the health care provider for not treating the condition more aggressively," said Turchin. "We find that the situation is far more complicated. The patient is at the center of their health care and makes their own health care decisions. When we think about improving health care, we must take into consideration that both the provider and patient are involved in these decisions."
Funding for this work was provided by Sanofi.

Paper cited: Turchin, A et al. "Predictors and consequences of declining of insulin therapy by individuals with type 2 diabetes" Diabetic Medicine DOI: 10.1111/dme.14260

Brigham Health, a global leader in creating a healthier world, consists of Brigham and Women's Hospital, Brigham and Women's Faulkner Hospital, the Brigham and Women's Physicians Organization and many related facilities and programs. With more than 1,000 inpatient beds, approximately 60,000 inpatient stays and 1.7 million outpatient encounters annually, Brigham Health's 1,200 physicians provide expert care in virtually every medical and surgical specialty to patients locally, regionally and around the world. An international leader in basic, clinical and translational research, Brigham Health has nearly 5,000 scientists, including physician-investigators, renowned biomedical researchers and faculty supported by over $700 million in funding. The Brigham's medical preeminence dates back to 1832, and now, with 19,000 employees, that rich history is the foundation for its commitment to research, innovation, and community. Boston-based Brigham and Women's Hospital is a teaching affiliate of Harvard Medical School and dedicated to educating and training the next generation of health care professionals. For more information, resources, and to follow us on social media, please visit

Brigham and Women's Hospital

Related Diabetes Articles:

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.
Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.
Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).
Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.
Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.
Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.
Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).
Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.
People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.
Diabetes, but not diabetes drug, linked to poor pregnancy outcomes
New research indicates that pregnant women with pre-gestational diabetes who take metformin are at a higher risk for adverse pregnancy outcomes -- such as major birth defects and pregnancy loss -- than the general population, but their increased risk is not due to metformin but diabetes.
More Diabetes News and Diabetes Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Power Of Spaces
How do spaces shape the human experience? In what ways do our rooms, homes, and buildings give us meaning and purpose? This hour, TED speakers explore the power of the spaces we make and inhabit. Guests include architect Michael Murphy, musician David Byrne, artist Es Devlin, and architect Siamak Hariri.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at     You can read The Transition Integrity Project's report here.